Drug concentration (µM) | % of motility on xL3s (average ± SEM)a | % of L4 development (average ± SEM)b | Adult stage motility score (average ± SEM)a | |
---|---|---|---|---|
Ivermectin | 1 | 25.8 ± 11.6c | 1.4 ± 2.7d | 0.7 ± 0.5e |
0.1 | 106.0 ± 21.7 | 37.0 ± 9.5d | 0.6 ± 0.2e | |
0.01 | 104.9 ± 23.5 | 66.9 ± 20.7 | 0.7 ± 0.4e | |
0.001 | NT | 86.7 ± 21.4 | 0.8 ± 0.3e | |
0.0001 | NT | NT | 1.3 ± 0.1e | |
Levamisole | 50 | 0.6 ± 1.6c | 0.0 ± 0.0d | NT |
5 | 72.6 ± 13.4 | 8.9 ± 3.7d | 0.0 ± 0.0e | |
0.5 | 128.1 ± 25.6 | 89.5 ± 3.1 | 0.0 ± 0.0e | |
0.005 | NT | NT | 1.9 ± 0.2 | |
0.0005 | NT | NT | 2.8 ± 0.1 | |
Monepantel | 2 | 3.5 ± 3.7c | 4.0 ± 1.1d | 0.3 ± 0.2e |
0.2 | 9.3 ± 7.1c | 20.1 ± 18.0d | 0.7 ± 0.2e | |
0.02 | 127.2 ± 26.3 | 85.5 ± 20.5 | 1.0 ± 0.2e | |
0.002 | NT | NT | 2.2 ± 0.1 | |
Albendazole sulfoxide | 36 | 37.5 ± 14.5c | 0.0 ± 0.0d | 1.0 ± 0.0e |
3.6 | 56.4 ± 13.5c | 1.9 ± 2.1d | 1.4 ± 0.3e | |
0.36 | 134.8 ± 27.5 | 55.1 ± 16.9d | 1.3 ± 0.2e | |
0.036 | 116.2 ± 20.2 | 74.5 ± 15.4 | 2.3 ± 0.0 |